ASCO 2023 | Comparison of response assessment criteria in glioblastoma: RANO, mRANO, and iRANO

Patrick Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses an evaluation of Response Assessment in Neuro-Oncology (RANO) criteria, modified RANO (mRANO) criteria, and immunotherapy RANO (iRANO) criteria in patients with newly diagnosed and recurrent glioblastoma. Correlations between progression-free survival (PFS) and overall survival (OS) were assessed. The results showed that RANO and mRANO had similar correlations with PFS and OS. Confirmation scans within 12 weeks of radiotherapy completion improved correlations in newly diagnosed cases. Using post-radiation MRI as the baseline scan also improved correlations. Evaluating fluid-attenuated inversion recovery (FLAIR) sequences did not enhance the correlation. In patients receiving immunotherapy, all three criteria showed similar correlations. These findings suggest that RANO and mRANO criteria are comparable and confirmatory scans and FLAIR evaluation may not be necessary. The iRANO criteria did not provide additional benefits for patients on immune checkpoint inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.